176 related articles for article (PubMed ID: 38770543)
21. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.
Sharma S; Katz R; Ginsberg C; Bullen A; Vallon V; Thomson S; Moe OW; Hoofnagle AN; de Leeuw PW; Kroon AA; Houben AJHM; Ix JH
J Bone Miner Res; 2022 Jun; 37(6):1170-1178. PubMed ID: 35373859
[TBL] [Abstract][Full Text] [Related]
22. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
Wolf M; Koch TA; Bregman DB
J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
[TBL] [Abstract][Full Text] [Related]
23. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)
Kritmetapak K; Losbanos L; Berent TE; Ashrafzadeh-Kian SL; Algeciras-Schimnich A; Hines JM; Singh RJ; Kumar R
BMC Nephrol; 2021 Mar; 22(1):114. PubMed ID: 33784965
[TBL] [Abstract][Full Text] [Related]
24. Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial.
Ramirez-Sandoval JC; Arvizu-Hernandez M; Cruz C; Vazquez-Cantu B; Rojas-Concha LJ; Tamez L; Reynerio F; Gomez FE; Correa-Rotter R
J Nephrol; 2019 Aug; 32(4):645-659. PubMed ID: 30888584
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D
Mager DR; Jackson ST; Hoffmann MR; Jindal K; Senior PA
Clin Nutr; 2017 Jun; 36(3):686-696. PubMed ID: 27302208
[TBL] [Abstract][Full Text] [Related]
26. Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients.
Tan SJ; Satake S; Smith ER; Toussaint ND; Hewitson TD; Holt SG
Eur J Clin Nutr; 2017 Feb; 71(2):180-184. PubMed ID: 27848940
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor 23 concentrations and modifying factors in children from age 12 to 24 months.
Enlund-Cerullo M; Hauta-Alus H; Valkama S; Rosendahl J; Andersson S; Mäkitie O; Holmlund-Suila E
Bone; 2020 Dec; 141():115629. PubMed ID: 32919110
[TBL] [Abstract][Full Text] [Related]
28. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
29. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations.
Bosman A; Ratsma DM; van der Eerden BC; Zillikens MC
JBMR Plus; 2023 Oct; 7(10):e10790. PubMed ID: 37808399
[TBL] [Abstract][Full Text] [Related]
31. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
Scholze A; Liu Y; Pedersen L; Xia S; Roth HJ; Hocher B; Rasmussen LM; Tepel M
J Clin Endocrinol Metab; 2014 May; 99(5):E855-61. PubMed ID: 24606097
[TBL] [Abstract][Full Text] [Related]
32. Biological variability of plasma intact and C-terminal FGF23 measurements.
Smith ER; Cai MM; McMahon LP; Holt SG
J Clin Endocrinol Metab; 2012 Sep; 97(9):3357-65. PubMed ID: 22689697
[TBL] [Abstract][Full Text] [Related]
33. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
Kanda E; Yoshida M; Sasaki S
BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
[TBL] [Abstract][Full Text] [Related]
34. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Vitamin D Supplementation on Bone Metabolic Markers in Chronic Kidney Disease.
Yadav AK; Kumar V; Kumar V; Banerjee D; Gupta KL; Jha V
J Bone Miner Res; 2018 Mar; 33(3):404-409. PubMed ID: 29044707
[TBL] [Abstract][Full Text] [Related]
36. Effects of Vitamin D
Batacchi Z; Robinson-Cohen C; Hoofnagle AN; Isakova T; Kestenbaum B; Martin KJ; Wolf MS; de Boer IH
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1498-1506. PubMed ID: 28768705
[TBL] [Abstract][Full Text] [Related]
37. Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism.
Fořtová M; Hanousková L; Valkus M; Čepová J; Průša R; Kotaška K
Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34860179
[TBL] [Abstract][Full Text] [Related]
38. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
Iwasaki T; Fujimori A; Nakanishi T; Okada S; Hanawa N; Hasuike Y; Kuragano T
BMC Nephrol; 2021 Apr; 22(1):124. PubMed ID: 33832448
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults.
Paul S; Wong M; Akhabue E; Mehta RC; Kramer H; Isakova T; Carnethon MR; Wolf M; Gutiérrez OM
J Am Heart Assoc; 2021 Aug; 10(16):e020196. PubMed ID: 34387090
[TBL] [Abstract][Full Text] [Related]
40. Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease.
Kamath N; Iyengar A; Reddy HV; Sharma J; Singhal J; Ekambaram S; Uthup S; Selvam S; Wan M; Rahn A; Christiane-Fischer D; Shroff R
Pediatr Nephrol; 2023 Jun; 38(6):1907-1913. PubMed ID: 36322258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
